Nothing Special   »   [go: up one dir, main page]

WO2007120823A3 - Uses and compositions for treatment of psoriasis - Google Patents

Uses and compositions for treatment of psoriasis Download PDF

Info

Publication number
WO2007120823A3
WO2007120823A3 PCT/US2007/009131 US2007009131W WO2007120823A3 WO 2007120823 A3 WO2007120823 A3 WO 2007120823A3 US 2007009131 W US2007009131 W US 2007009131W WO 2007120823 A3 WO2007120823 A3 WO 2007120823A3
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
treatment
compositions
methods
subject
Prior art date
Application number
PCT/US2007/009131
Other languages
French (fr)
Other versions
WO2007120823A2 (en
Inventor
Mary Kaye Willian
Martin M Okun
Rebecca S Hoffman
Original Assignee
Abbott Biotech Ltd
Mary Kaye Willian
Martin M Okun
Rebecca S Hoffman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotech Ltd, Mary Kaye Willian, Martin M Okun, Rebecca S Hoffman filed Critical Abbott Biotech Ltd
Priority to EP07755413A priority Critical patent/EP2012824A4/en
Publication of WO2007120823A2 publication Critical patent/WO2007120823A2/en
Publication of WO2007120823A3 publication Critical patent/WO2007120823A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment psoriasis in a subject.
PCT/US2007/009131 2006-04-10 2007-04-10 Uses and compositions for treatment of psoriasis WO2007120823A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07755413A EP2012824A4 (en) 2006-04-10 2007-04-10 Uses and compositions for treatment of psoriasis

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US79090906P 2006-04-10 2006-04-10
US60/790,909 2006-04-10
US80977006P 2006-05-30 2006-05-30
US60/809,770 2006-05-30
US81548906P 2006-06-20 2006-06-20
US60/815,489 2006-06-20
US81789106P 2006-06-29 2006-06-29
US60/817,891 2006-06-29
US84012206P 2006-08-25 2006-08-25
US60/840,122 2006-08-25
US89926207P 2007-02-02 2007-02-02
US60/899,262 2007-02-02
US90968307P 2007-04-02 2007-04-02
US60/909,683 2007-04-02

Publications (2)

Publication Number Publication Date
WO2007120823A2 WO2007120823A2 (en) 2007-10-25
WO2007120823A3 true WO2007120823A3 (en) 2008-10-02

Family

ID=38610206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/009131 WO2007120823A2 (en) 2006-04-10 2007-04-10 Uses and compositions for treatment of psoriasis

Country Status (2)

Country Link
EP (1) EP2012824A4 (en)
WO (1) WO2007120823A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126372A1 (en) * 2002-07-19 2004-07-01 Abbott Biotechnology Ltd. Treatment of TNFalpha related disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201705980A (en) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 Multiple-variable dose regimen for treating TNF[alpha]-related disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126372A1 (en) * 2002-07-19 2004-07-01 Abbott Biotechnology Ltd. Treatment of TNFalpha related disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOTTLIEB A.B.: "The National Psoriasis Foundation Psoriasis Score System versus the Psoriasis Area Severity Index and Physician's Global Assessment: a comparison", June 2003 (2003-06-01) *
See also references of EP2012824A4 *

Also Published As

Publication number Publication date
WO2007120823A2 (en) 2007-10-25
EP2012824A4 (en) 2010-06-16
EP2012824A2 (en) 2009-01-14

Similar Documents

Publication Publication Date Title
WO2008063213A3 (en) Uses and compositions for treatment of psoriatic arthritis
WO2007120626A3 (en) Uses and compositions for treatment of ankylosing spondylitis
WO2007120656A3 (en) Uses and compositions for treatment of rheumatoid arthritis
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
WO2008154543A3 (en) Methods for treating juvenile idiopathic arthritis
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2007092622A3 (en) Compositions and methods for treating bone
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
WO2009118662A3 (en) Methods and compositions for treating bone loss
WO2008150490A3 (en) Uses and compositions for treatment of psoriasis and crohn's disease
WO2006042249A3 (en) Methods and compositions for treating migraine pain
WO2007120651A3 (en) Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2008030505A8 (en) Methods and compositions for the treatment of antibody mediated neuropathies
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
WO2007051065A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2010048026A3 (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
NO20075304L (en) Method of decreasing calcification
WO2006052718A8 (en) Farnesyltransferase inhibitors for treating sepsis
WO2009079451A3 (en) Compositions and methods of promoting wound healing
WO2006028524A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2010032011A8 (en) Anti-fungal therapy
WO2007112121A3 (en) Tetracycline compounds and methods of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07755413

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007755413

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)